Literature DB >> 15372867

Ability of clinical pharmacists in a community pharmacy setting to manage anticoagulation therapy.

Nadia A Amruso1.   

Abstract

OBJECTIVES: To determine the ability of community pharmacists within an anticoagulation clinic to keep international normalized ratios (INRs) within therapeutic ranges and, secondarily, to determine the incidence of bleeding and thromboembolic events and patient satisfaction.
DESIGN: Retrospective observational study.
SETTING: Eckerd PatientCARE Network in Eckerd pharmacies in Tampa Bay area of Florida. PATIENTS: 50 patients taking warfarin and having INR determinations for 6 consecutive months.
INTERVENTIONS: Clinical pharmacists monitored patients' anticoagulation status using point-of-care analyzers and making dosage changes as needed under a collaborative agreement. Extensive patient education was provided to patients regarding their anticoagulation. Data were collected from the initial visit through the 6 consecutive months. Patients were surveyed to assess their satisfaction with the clinic. MAIN OUTCOME MEASURES: Percentage of INRs within therapeutic range and, secondarily, incidence of bleeding and thromboembolic events and patient satisfaction with the clinic.
RESULTS: During the 6 months of initial therapy with warfarin, 243 of 435 (56%) INRs were in desired therapeutic ranges. A total of 15 bleeding episodes were reported, of which 10 were minor and 5 were significant. No thromboembolic events were reported. There was a 22% response rate to the survey, in which all statements were rated as above average to excellent.
CONCLUSION: Community pharmacists in an anticoagulation clinic effectively manage anticoagulation therapy, as the results of this clinic are similar to those of clinics managed by pharmacists in other settings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372867     DOI: 10.1331/1544345041475751

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  8 in total

Review 1.  Clinical applications of pharmacogenomics guided warfarin dosing.

Authors:  Pramod Mahajan; Kristin S Meyer; Geoffrey C Wall; Heidi J Price
Journal:  Int J Clin Pharm       Date:  2010-11-04

Review 2.  Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance.

Authors:  Jennifer L Donovan; Julie A Drake; Peter Whittaker; Maichi T Tran
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

Review 3.  Clinical applications of pharmacogenomics guided warfarin dosing.

Authors:  Pramod Mahajan; Kristin S Meyer; Geoffrey C Wall; Heidi J Price
Journal:  Int J Clin Pharm       Date:  2011-02-04

Review 4.  Best strategies for patient education about anticoagulation with warfarin: a systematic review.

Authors:  James L Wofford; Megan D Wells; Sonal Singh
Journal:  BMC Health Serv Res       Date:  2008-02-14       Impact factor: 2.655

5.  Evaluation of a continuous quality improvement program in anticoagulant therapy: Feasibility, satisfaction and perception.

Authors:  Ariane Cantin; Alexandre Lahaie; Bojan Odobasic; Marie-Philip Tremblay; Dana Wazzan; Stéphanie Caron; Caroline Leblanc; Josée Martineau; Lyne Lalonde
Journal:  Can Pharm J (Ott)       Date:  2016-10-06

Review 6.  Community pharmacy: an untapped patient data resource.

Authors:  David John Wright; Michael James Twigg
Journal:  Integr Pharm Res Pract       Date:  2016-03-07

7.  Patients' and physicians' satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic.

Authors:  Lisa Bishop; Stephanie Young; Laurie Twells; Carla Dillon; John Hawboldt
Journal:  BMC Res Notes       Date:  2015-06-09

8.  Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service.

Authors:  Samantha J Ingram; Charlotte L Kirkdale; Sian Williams; Elaine Hartley; Susan Wintle; Valerie Sefton; Tracey Thornley
Journal:  BMC Health Serv Res       Date:  2018-02-07       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.